ARTIVA BIOTHERAPEUTICS, INC.
12.30%
5,999,703
1817241
May 10, 2026
May 28, 2026, 04:38 PM
Reporting Persons (3)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| GC Corp | Holding Company | 12.30% | 5,999,703 | 0 | 5,999,703 |
| Yong-Jun Huh | Individual | 12.30% | 5,999,703 | 0 | 5,999,703 |
| GC Cell Corporation | CO | 3.30% | 1,607,734 | 0 | 1,607,734 |
Disclosure Items (5)
Common Stock
ARTIVA BIOTHERAPEUTICS, INC.
5505 Morehouse Drive, Suite 100, San Diego, CA, 92121
This Schedule 13D is being filed on behalf of GC Corp., GC Cell Corporation and Yong-Jun Huh. GC Corp., GC Cell Corporation and Yong-Jun Huh are collectively referred to herein as the "Reporting Persons." The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, (the "Act"), is attached hereto as Exhibit 99.1. The Reporting Persons' beneficial ownership of the Issuer's Common Stock consists of (i) 4,391,969 shares of Common Stock directly held by GC Corp. and (ii) 1,607,734 shares of Common Stock directly held by GC Cell Corporation. Mr. Yong-Jun Huh serves as Chief Executive Officer of GC Corp. and is a member of the board of directors of GC Corp. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors. Mr. Yong-Jun Huh may be deemed beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by GC Corp. and GC Cell Corporation. Mr. Yong-Jun Huh disclaims beneficial ownership of the securities reported in this Schedule 13D other than for the purpose of determining his obligations under Section 13(d) of the Act, and the filing of this Schedule 13D shall not be deemed an admission that Mr. Yong-Jun Huh is the beneficial owner of such securities for any other purpose.
On May 11, 2026, GC Corp purchased 1,085,069 shares of Common Stock at a price of $11.52 per share from the underwriters of the Issuer's underwritten offering (the "May 2026 Offering") and GC Cell Corporation purchased 347,222 shares of Common Stock at a price of $11.52 per share in the May 2026 Offering. The aggregate purchase price for all securities acquired by GC Corp and GC Cell Corporation in the May 2026 Offering was $16,499,992.32, which was funded by the working capital of GC Corp.
The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D/A is incorporated by reference. The percentage set forth in row 13 is based on 48,588,198 shares of Common Stock outstanding upon the closing of the May 2026 Offering described in the Issuer's prospectus supplement filed with the Securities and Exchange Commission on May 8, 2026.
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D/A and Item 2 above is incorporated by reference.
Except as set forth herein, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.
No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock subject to this Schedule 13D/A.
Not applicable
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 1 to the Reporting Persons' Schedule 13D filed with the SEC on July 29, 2024).